Application of AMHR2 recombinant protein or fused protein in preparation of drugs for treating AMH signal axis abnormal activation related diseases

A technology of recombinant protein and fusion protein, which is applied in diseases, drug combinations, peptide/protein components, etc. It can solve the problems of unknown, undisclosed or prompted biological effects, and achieve excellent in vivo stability, long half-life, and binding force. strong effect
CN111000982AInactive Publication Date: 2020-04-14PHARCHOICE THERAPEUTICS INC
1 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
PHARCHOICE THERAPEUTICS INC
Publication Date
2020-04-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to application of an AMHR2 recombinant protein or fused protein in the preparation of drugs for treating AMH signal axis abnormal activation related diseases, and especially application in the preparation of AMH neutralizers or antagonists. Stability experiments show that the AMHR2 fused protein is long in half-life period, excellent in in-vivo stability and strong in AMH binding force, and has certain druggability. Cell experiments and animal model experiments show that the AMHR2 recombinant protein or the AMHR2 fused protein can effectively antagonize or neutralize AMHin vitro and vivo, can further block an AMH signal axis, and can effectively prevent and treat diseases caused by abnormal activation of the AMH signal axis.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biomedical engineering, in particular to recombinant AMHR2 and AMHR2 fusion protein, a pharmaceutical composition using it as an active component and its medical application, especially the application for diseases related to abnormal activation of AMH signaling axis. Background technique

[0002] Anti-Müllerian hormone (AMH), also known as Müllerian Inhibiting Substance (MIS), is a TGF-β family glycoprotein. AMH receptors include receptor complexes of type I receptors and type II receptors, wherein the type II receptor is AMHR2, and multiple type I receptors participate in signal transduction. AMH induces Müllerian regression in human male embryos but is expressed in females of reproductive age, does not fluctuate with cycle or pregnancy, and gradually decreases with both oocyte quantity and quality, suggesting that AMH can be used as a marker of ovarian physiology. Mark. See literature eg [Zec et al, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More